Navigation Links
arGEN-X Initiates Phase IbStudy of ARGX-111 in Cancer
Date:9/17/2013

, including complex receptors and highly conserved targets often intractable with other antibody technologies. SIMPLE Antibody™ generated leads are further differentiated as products through enhancement of cell killing properties (POTELLIGENT®, licensed from BioWa Inc.) and optimization of circulation time and distribution in the body (NHance™). ArGEN-X is also developing ABDEG™ technology, to potentiate the clearance of disease-causing autoantibodies.

In January 2013, arGEN-X initiated a Phase Ib clinical trial for ARGX-110, its most advanced SIMPLE Antibody™ program modulating CD70 via a unique mode of action in hematological and virally-induced solid tumors. A second CTA for ARGX-111, a novel anti-c-Met antibody to treat diverse solid tumors, is the subject of this press release.

The SIMPLE Antibody™ platform is covered by broad patent claims, enjoys an independent, unencumbered patent position and is free of target gatekeeping restrictions.

SIMPLE stands for Superior Immunodiversity with Minimal Protein Lead Engineering.

arGEN-X™, SIMPLE Antibody™ and NHance™ are deposited trademarks of arGEN-X BV.

For further information, please contact:

Citigate Dewe Rogerson
David Dible
Mark Swallow
Nina Enegren
T: +44(0)207-282-2949/2948/1050
E: david.dible@citigatedr.co.uk

arGEN-X
Tim Van Hauwermeiren, MSc, eMBA
Chief Executive Officer
T: +31-6-122-85-257
E: tim.vh@arGEN-X.com

Alain Thibault, M.D.
Chief Medical Officer
T: +32-471-81-71-24
E: athibault@argen-x.com



'/>"/>
SOURCE arGEN-X
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. arGEN-X Appoints Dr. David L. Lacey to its Supervisory Board
2. arGEN-X Announces Preclinical Development of ARGX-112 for Dermatology
3. arGEN-X Identifies Potent Antibody Antagonists against Complex Chronic Pain Target Nav1.7
4. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
5. CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
6. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
7. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
8. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
9. MAQUET Initiates Class I Recall of the FLOW-i Anesthesia System
10. Stryker Initiates Voluntary Product Recall of Modular-Neck Stems
11. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Mass. , Nov. 25, 2014 Reinforcing ... Royal Philips (NYSE: PHG AEX: ... and Drug Administration (FDA) for its IQon Spectral ... imaging. This first-of-its kind technology adds a new dimension ... offering the ability to characterize structures based on their ...
(Date:11/26/2014)... , Nov. 25, 2014  Array BioPharma ... announced that its Chief Executive Officer, ... following upcoming conferences.  The public is welcome ... on the Array BioPharma website:  www.arraybiopharma.com ... 2014Time:1:30 p.m.  Eastern Time Location: Palace Hotel, ...
(Date:11/26/2014)... Nov. 25, 2014 Halozyme Therapeutics, Inc. (NASDAQ: ... Healthcare Conference in New York on ... . Dr. Helen Torley , President and Chief ... presentation will be webcast through the "Investors" section of Halozyme,s ... be made available for 90 days following the event. To ...
Breaking Medicine Technology:Philips receives FDA 510(k) clearance for IQon Spectral CT 2Philips receives FDA 510(k) clearance for IQon Spectral CT 3Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2
... Feb. 23, 2012  BioSpecifics Technologies Corp. (NASDAQ: ... in class collagenase-based products marketed as XIAFLEX® in ... today announced that its partner Auxilium Pharmaceuticals, Inc. ... Pharmaceuticals Ltd. (Actelion) for the long-term development, supply ...
... Feb. 23, 2012 Idenix Pharmaceuticals, Inc. (NASDAQ: ... discovery and development of drugs for the treatment of ... the fourth quarter and year ended December 31, 2011 ... virus (HCV) development pipeline. Operational ...
Cached Medicine Technology:BioSpecifics Announces Partnership Between Auxilium and Actelion for XIAFLEX® in Canada, Australia, Brazil and Mexico 2BioSpecifics Announces Partnership Between Auxilium and Actelion for XIAFLEX® in Canada, Australia, Brazil and Mexico 3BioSpecifics Announces Partnership Between Auxilium and Actelion for XIAFLEX® in Canada, Australia, Brazil and Mexico 4Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 2Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 3Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 4Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 5Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 6Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 7Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 8
(Date:11/26/2014)... DC (PRWEB) November 26, 2014 For ... (AIS) independently published The AIS Report on Blue Cross ... and WellPoint, Inc. on the varied strategies the two ... and improve compliance with treatments for sleep apnea, ranging ... sleep disorder, because it’s linked to increased rates of ...
(Date:11/26/2014)... Senior Planning Services, providing “expert guidance for elder ... the adult demographic education and access to computer ... rough seas of applying for Medicaid. Part of this ... of Medicaid eligibility and proper planning, while also helping ... this coverage. , Senior Planning Services has made ...
(Date:11/26/2014)... California (PRWEB) November 26, 2014 Medical ... of 3.9 out of 5. This score represents steady ... the three years to 2014 as a result of ... medical suction machines, which are largely considered nondiscretionary. IBISWorld ... purchasing process, buyers have some degree of flexibility, given ...
(Date:11/26/2014)... Sonoran Vein and Endovascular nurse, Jennifer ... Preceptorship Award from The American Association of ... advancement of nurse practitioners. The Distinguished Preceptorship Award ... made a significant contribution toward increasing the awareness ... Nurse Practitioners (AANP) is the largest full-service national ...
(Date:11/26/2014)... -- The number of emergency department visits in the United ... record 136 million in 2011, according to the U.S. Centers ... that fewer people were going to ERs with non-urgent medical ... care within two hours of arriving at the ER. In ... Sixty percent of patients arrived at the ER after ...
Breaking Medicine News(10 mins):Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 2Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 3Health News:Senior Planning Services Teams Up with SeniorNet To Educate Seniors On Medicaid Planning 2Health News:Medical Suction & Vacuum Products Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Medical Suction & Vacuum Products Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Medical Suction & Vacuum Products Procurement Category Market Research Report from IBISWorld has Been Updated 4Health News:Sonoran Nurse Receives Distinguished Preceptorship Award from The American Association of Nurse Practitioners 2Health News:ER Visits on the Rise, Study Reports 2
... Company,(Nasdaq: PRGO ; TASE) today announced that it ... Cream 0.1%, a generic version of,VANOS(R) Cream 0.1%. The ... an,ANDA with a Paragraph IV certification against VANOS(R)., ... to relieve the inflammation and itching caused by certain,skin ...
... suggest current dietary requirements need to be increased , , MONDAY, ... the risk of heart attack in men, says a U.S. ... and Brigham and Women,s Hospital, Boston, analyzed medical records and ... had a nonfatal heart attack or fatal heart disease, and ...
... Francisco, Calif., June 07, 2008 Results from ... announced today at the American Diabetes Association (ADA) ... Development Center, Inc. Alogliptin, which has been ... dipeptidyl peptidase-4 (DPP-4), is currently under investigation as ...
... June 9 The Department of,Labor & Industry invites the ... the 10th annual Health & Safety Day from 10 a.m. ... Wing Rotunda in,Harrisburg., The event will feature an array ... home. Visitors to the event can,receive - free of charge ...
... wheel, with 2.2% reporting accidents as result , , MONDAY, June ... of sleep may be a real problem for American college ... at the University of North Texas found that 17 percent ... that group reported having accidents because of this drowsiness. A ...
... College of Physicians (ACP) today pledged its support for ... Patients and Providers Act of 2008. , "The College ... addresses and incorporates three of our top legislative priorities," ... Max Baucus (D-MT), chairman of the Senate Finance Committee. ...
Cached Medicine News:Health News:Perrigo Confirms Filing for Generic Version of VANOS(R) 2Health News:Phase 3 results for alogliptin 2Health News:Phase 3 results for alogliptin 3Health News:Sleepy Driving Prevalent Among Collegians 2Health News:ACP pledges support for Medicare improvements for Patients and Providers Act of 2008 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: